The Journal of rheumatology · 2026
Remission Rates of Patients With Axial Spondyloarthritis in a Tertiary Care Center.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kluempers Franziska, Redeker Imke, Puravath Abin P, Calixto Omar Javier, Tsiami Styliani, Kiefer David, Baraliakos Xenofon, Kiltz Uta
Аннотация
OBJECTIVE: To evaluate remission rates in axial spondyloarthritis (axSpA) using cross-sectional data.
METHODS: Adult patients with axSpA and ≥ 2 prior visits were included. Patient characteristics and outcome measures for disease activity and physical function were documented at enrollment (enrollment visit). Remission was defined as an Axial Spondyloarthritis Disease Activity Score (ASDAS) < 1.3 and sustained remission as an ASDAS < 1.3 for ≥ 6 consecutive months. Multivariable logistic regression was used to estimate odds ratios (ORs), 95% CIs, and P values for factors associated with remission.
RESULTS: A total of 200 patients were studied for a mean of 82.6 (SD 58.6) months. Mean ASDAS at the enrollment visit was 2.0 (SD 1.0). A total of 117 patients (58.5%) achieved ASDAS remission at least once during observation. Remission was reached 37.7 (SD 44.5) months after the start of treatment at our hospital (index visit). A total of 44 patients achieved remission within the first year (37.6%), 20 (17.1%) after the first year, 13 (11.1%) after 2 years, and 40 (34.2%) after 3 years. Mean remission duration was 9.9 (SD 16.8) months. A total of 51 patients (43.6%) achieved sustained remission for ≥ 6 consecutive months. High C-reactive protein (CRP; OR 1.35 [95% CI 1.10-1.73]) and lower Bath Ankylosing Spondylitis Disease Activity Index (BASDAI; OR 0.72 [95% CI 0.53-0.97]) at the index visit were associated with achieving remission at least once.
CONCLUSION: Remission is an attainable outcome for patients with axSpA in usual care. High CRP and low BASDAI at the index visit were associated with remission. Most patients were in remission within the first 2 years of treatment, but first remission for some patients occurred after > 5 years of follow-up.
METHODS: Adult patients with axSpA and ≥ 2 prior visits were included. Patient characteristics and outcome measures for disease activity and physical function were documented at enrollment (enrollment visit). Remission was defined as an Axial Spondyloarthritis Disease Activity Score (ASDAS) < 1.3 and sustained remission as an ASDAS < 1.3 for ≥ 6 consecutive months. Multivariable logistic regression was used to estimate odds ratios (ORs), 95% CIs, and P values for factors associated with remission.
RESULTS: A total of 200 patients were studied for a mean of 82.6 (SD 58.6) months. Mean ASDAS at the enrollment visit was 2.0 (SD 1.0). A total of 117 patients (58.5%) achieved ASDAS remission at least once during observation. Remission was reached 37.7 (SD 44.5) months after the start of treatment at our hospital (index visit). A total of 44 patients achieved remission within the first year (37.6%), 20 (17.1%) after the first year, 13 (11.1%) after 2 years, and 40 (34.2%) after 3 years. Mean remission duration was 9.9 (SD 16.8) months. A total of 51 patients (43.6%) achieved sustained remission for ≥ 6 consecutive months. High C-reactive protein (CRP; OR 1.35 [95% CI 1.10-1.73]) and lower Bath Ankylosing Spondylitis Disease Activity Index (BASDAI; OR 0.72 [95% CI 0.53-0.97]) at the index visit were associated with achieving remission at least once.
CONCLUSION: Remission is an attainable outcome for patients with axSpA in usual care. High CRP and low BASDAI at the index visit were associated with remission. Most patients were in remission within the first 2 years of treatment, but first remission for some patients occurred after > 5 years of follow-up.